FCGR3A and acute myeloid leukemia: In the manuscript, AML patients with expanded CD56neg CD16+ NK cells group had significantly poorer overall survival (HR[CI95]=3.3[0.75-14.7], p=0.0251) and relapse-free survival (HR[CI95]=13.1[1.9-87.5], p=0.0079) after 36 months follow-up (60).